ZNF217
ZNF217 (Zinc finger protein 217) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer and Osteosarcoma.
Overview
Binds to the promoters of target genes and functions as repressor. Promotes cell proliferation and antagonises cell death. Promotes phosphorylation of AKT1 at 'Ser-473'.
CIViC holds 4 clinical evidence items and 0 assertions across 2 variants, naming Triciribine. Open Targets scores its association with cancer at 0.53 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.66).
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · ZNF217 (Zinc finger protein 217) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer and Osteosarcoma.
- 1 · What it is
ZNF217 (Zinc finger protein 217) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer and Osteosarcoma.
- 2 · What goes wrong in cancer
Binds to the promoters of target genes and functions as repressor. Promotes cell proliferation and antagonises cell death.
- 3 · How drugs use it
No product in this corpus aims at ZNF217 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:13009 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O75362 (protein name, function text, keywords and locations (REST API)); CIViC gene ZNF217 (4 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, Ovarian Cancer, Osteosarcoma (GraphQL API, CC0)); Open Targets ENSG00000171940 (association with cancer (MONDO_0004992) 0.53; (GraphQL API, CC0))
Biology
Binds to the promoters of target genes and functions as repressor. Promotes cell proliferation and antagonises cell death. Promotes phosphorylation of AKT1 at 'Ser-473'. Location: Nucleus (UniProt). Locus 20q13.2 (HGNC).
- Breast cancer: CIViC evidence names this disease
- Ovarian cancer: CIViC evidence names this disease
- Osteosarcoma: CIViC evidence names this disease
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; CIViC holds 4 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"ZNF217" OR ABSTRACT:"ZNF217" OR TITLE:"zinc finger protein 217" OR ABSTRACT:"zinc finger protein 217" OR TITLE:"Zinc finger protein 217" OR ABSTRACT:"Zinc finger protein 217" OR TITLE:"ZABC1" OR ABSTRACT:"ZABC1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZNF217, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetRECQL4
Shares Osteosarcoma, Breast cancer (all types), Ovarian cancer, Open Targets Platform.
- TargetALDH2
Shares Osteosarcoma, Open Targets Platform.
- TargetSQSTM1
Shares Osteosarcoma, Open Targets Platform.
- TargetERCC2
Shares Osteosarcoma, CIViC, Ovarian cancer, Open Targets Platform.
- TargetCXCL10
Shares Osteosarcoma, CIViC.